Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7594 DPI 55μg/50μg · 1 trial · 1 indication
Trough value was defined as the mean of the 2 measurements 30 minutes apart (23 hours after last dose) pre-dose for every visit throughout the Treatment Period (Visit 4/Week 2 to Visit 7/Week 12). Baseline was defined as the mean of the 2 measured values before first IP administration (30 minutes apart, at -45 minutes and -15 minutes, before IP administration) on Day 1 (Visit 3). Analyses were based on a Mixed-effects model for repeated measures (MMRM) with treatment, visit, treatment by visit interaction and region as fixed effects, and baseline value and baseline by visit interaction as covariates. To investigate the clinical efficacy of AZD7594 at different dose levels in asthmatics symptomatic on low dose Inhaled corticosteroid (ICS).
| Arm | Type | Description |
|---|---|---|
| AZD7594 Dose 1 | EXPERIMENTAL | The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily. |
| AZD7594 Dose 2 | EXPERIMENTAL | The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily. |
| AZD7594 Dose 3 | EXPERIMENTAL | The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily. |
| AZD7594 Dose 4 | EXPERIMENTAL | The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily. |
| AZD7594 Dose 5 | EXPERIMENTAL | The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily. |
| Placebo | PLACEBO_COMPARATOR | The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily. |
| Fluticasone Furoate | ACTIVE_COMPARATOR | The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label). |
| Name | Type | Description |
|---|---|---|
| AZD7594 DPI 55μg/50μg. | DRUG | A non-steroidal and selective modulator of the GR. |
| AZD7594 DPI 99 µg/90 µg | DRUG | A non-steroidal and selective modulator of the GR. |
| AZD7594 DPI 198 µg/180 µg | DRUG | A non-steroidal and selective modulator of the GR. |
| AZD7594 DPI 396 µg/360 µg once daily. | DRUG | A non-steroidal and selective modulator of the GR. |
| AZD7594 DPI 792 µg/720 µg | DRUG | A non-steroidal and selective modulator of the GR. |
| Placebo for AZD7594 once daily. | DRUG | Placebo for AZD7594 |
| FF 100 µg once daily (open-label) | DRUG | Fluticasone furoate |
Inclusion criteria 1\. Provision of informed consent prior to any study-specific procedures 2. Men and women 18 to 85 years of age, inclusive, with body mass index (BMI)≤35 3. Subjects need to be non-smokers or ex-smokers (have quit e cigarettes or other inhaled tobacco products ≥6 months before Vi...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
AZD7594 DPI 55μg/50μg is an investigational inhaled therapy being studied for the treatment of asthma. It is a dry powder inhaler formulation developed by AstraZeneca and has been evaluated in adults with asthma in a Phase 2 clinical trial.
AZD7594 DPI 55μg/50μg is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this inhaled asthma candidate.
AZD7594 DPI 55μg/50μg is in Phase 2 development. It is an investigational drug and is not approved for commercial use. The Phase 2 trial evaluating it in asthma has been completed, and no active trials for this asset are currently listed.
AZD7594 DPI 55μg/50μg was evaluated in the Phase 2 trial NCT03622112, titled A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects. The trial enrolled 808 participants across the United States, Bulgaria, Germany, Hungary, Japan, Poland, South Africa, and Ukraine, and is completed.
The Phase 2 trial NCT03622112 was a randomized, double-blind, placebo-controlled study of multiple dose levels of AZD7594 given once daily by inhalation to adults with asthma. It enrolled 808 participants aged 18 years and older of all sexes and did not include healthy volunteers.
AZD7594 DPI 55μg/50μg is an alternative name for the same asset, referring to the dry powder inhaler presentation of AZD7594 at the 55μg/50μg dose. Both names refer to the AstraZeneca inhaled asthma candidate studied in the Phase 2 trial NCT03622112.